Our Story

Kath joined Brandon Capital in 2016.

Prior to joining, Katherine worked in academia in the field of experimental stroke. She spent 5 years at Weill Cornell Medicine-New York Presbyterian Hospital as a NHMRC CJ Martin and American Australian Association Sir Keith Murdoch fellow where she focused on the impact of progranulin deficiency (a known cause of certain subtypes of dementia), on cerebral vascular integrity and susceptibility to stroke.

Upon her return to Australia Katherine joined the Florey Institute of Neuroscience and Mental Health and began establishing herself as an independent researcher. During her time in academia, she published multiple research articles in top tier journals including J Neurosci & Stroke and secured competitive research funding from both the NHMRC and Brain Foundation of Australia.

Katherine is a Director of NRG Therapeutics and Phrenix Therapeutics and a board observer of  AstronauTx.

Katherine has a Bachelor of Science (First-class Honours) from The University of Melbourne, a PhD in Pharmacology from The University of Melbourne and an MBA (Deans’ Honours list) from the Melbourne Business School. Katherine received Dean’s commendations in macroeconomics, business law, operations and entrepreneurship. Katherine is a graduate of the Australian Institute of Company Directors.